Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica.
Kolde
Gerhard
G
Muche
J Marcus
JM
Schulze
Peter
P
Fischer
Peter
P
Lichey
Jürgen
J
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D007871:Leg Ulcer / Q000473:pathology; D008297:Male; D009335:Necrobiosis Lipoidica / Q000188:drug therapy* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab